Siddhartha Mukherjee (Brian Ach/Getty Images for The New Yorker)
All Blue's $733M bid to acquire Zymeworks turns hostile as board battles back — after a biotech celebrity jumps in
Yesterday, the team at All Blue Capital — bent on the takeover of a badly battered Zymeworks — brought in celebrated oncologist, Pulitzer prize-winning writer and biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
